JP2015083580A5 - - Google Patents

Download PDF

Info

Publication number
JP2015083580A5
JP2015083580A5 JP2014245645A JP2014245645A JP2015083580A5 JP 2015083580 A5 JP2015083580 A5 JP 2015083580A5 JP 2014245645 A JP2014245645 A JP 2014245645A JP 2014245645 A JP2014245645 A JP 2014245645A JP 2015083580 A5 JP2015083580 A5 JP 2015083580A5
Authority
JP
Japan
Prior art keywords
constipation
pharmaceutical
medicament
functional
glucopyranosyloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014245645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015083580A (ja
JP6105546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2014245645A priority Critical patent/JP6105546B2/ja
Priority claimed from JP2014245645A external-priority patent/JP6105546B2/ja
Publication of JP2015083580A publication Critical patent/JP2015083580A/ja
Publication of JP2015083580A5 publication Critical patent/JP2015083580A5/ja
Application granted granted Critical
Publication of JP6105546B2 publication Critical patent/JP6105546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014245645A 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途 Active JP6105546B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2014245645A JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012105847 2012-05-07
JP2014245645A JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014514708A Division JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (3)

Publication Number Publication Date
JP2015083580A JP2015083580A (ja) 2015-04-30
JP2015083580A5 true JP2015083580A5 (enExample) 2016-06-16
JP6105546B2 JP6105546B2 (ja) 2017-03-29

Family

ID=49550709

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014514708A Active JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途
JP2014245645A Active JP6105546B2 (ja) 2012-05-07 2014-12-04 ピラゾール誘導体及びその医薬用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014514708A Active JP5663699B2 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Country Status (15)

Country Link
US (2) US9273085B2 (enExample)
EP (1) EP2848254B1 (enExample)
JP (2) JP5663699B2 (enExample)
KR (1) KR101868991B1 (enExample)
CN (1) CN104284665B (enExample)
AU (1) AU2013258566B2 (enExample)
BR (1) BR112014027841B1 (enExample)
CA (1) CA2872002C (enExample)
DK (1) DK2848254T3 (enExample)
ES (1) ES2601127T3 (enExample)
MX (1) MX359988B (enExample)
PL (1) PL2848254T3 (enExample)
PT (1) PT2848254T (enExample)
RU (1) RU2602739C2 (enExample)
WO (1) WO2013168671A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012064266A1 (en) 2010-11-04 2012-05-18 Albireo Ab Ibat inhibitors for the treatment of liver diseases
PT2848254T (pt) * 2012-05-07 2016-10-05 Kissei Pharmaceutical Derivado de pirazol e utilização do mesmo para propósitos médicos
RU2648467C2 (ru) 2013-02-04 2018-03-26 Тайсо Фармасьютикал Ко., Лтд. Профилактическое или терапевтическое лекарственное средство для лечения запора
US20170143738A1 (en) * 2014-06-25 2017-05-25 Ea Pharma Co., Ltd. Solid formulation and method for stabilizing the same
KR102560954B1 (ko) 2014-06-25 2023-07-31 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
WO2019191352A1 (en) 2018-03-28 2019-10-03 Avolynt Method for treating post-prandial hypoglycemia
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
AU2020218908B2 (en) 2019-02-06 2025-01-23 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
DK4069360T3 (da) 2019-12-04 2024-02-26 Albireo Ab Benzothia(di)azepinforbindelser og anvendelse deraf som galdesyremodulatorer
CA3186857A1 (en) 2020-08-03 2022-02-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
JP2024500309A (ja) 2020-12-04 2024-01-09 アルビレオ エービー ベンゾチア(ジ)アゼピン化合物および胆汁酸モジュレータとしてのその使用
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
CA2650295C (en) * 2006-04-26 2015-12-29 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
BRPI0821773B8 (pt) * 2007-12-27 2021-05-25 Kissei Pharmaceutical monossebacato cristalino de bis[3-(3-{4-[3-(beta-dglicopiranosilóxi)-5-isopropil-1h-pirazol-4-ilmetil]-3-metilfenóxi}propilamino)-2,2-dimetil-propionamida], composição farmacêutica e medicamento compreendendo o dito composto
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の1/2フマル酸塩
TW201105336A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Combined medicine of pyrazole derivative and biguanide drug
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
PT2848254T (pt) * 2012-05-07 2016-10-05 Kissei Pharmaceutical Derivado de pirazol e utilização do mesmo para propósitos médicos

Similar Documents

Publication Publication Date Title
JP2015083580A5 (enExample)
ES2601127T3 (es) Derivado de pirazol y su uso con fines médicos
JP2015523407A5 (enExample)
JP2015057451A5 (enExample)
CN110036005A (zh) 酰胺衍生物及其在药物中的应用
NZ780890A (en) Pharmaceutical compositions comprising meloxicam
JP2016106150A5 (enExample)
JP2012193216A5 (enExample)
JP2017506624A5 (enExample)
CN109982699A (zh) 一种mor激动剂与kor激动剂的药物组合物及其用途
CN111836807A (zh) 氧杂螺环类化合物及其制备方法和用途
JP2018537507A5 (enExample)
JP2014198723A5 (enExample)
JP2017014206A5 (enExample)
RU2014141893A (ru) Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法
JP2013166781A5 (enExample)
JP2018521007A5 (enExample)
JP2019218379A5 (enExample)
JP2018531273A5 (enExample)
JP2016540000A5 (enExample)
RU2018126158A (ru) Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени
JP2016538288A5 (enExample)
JP2013032308A5 (enExample)
JP2016540799A5 (enExample)